| Characteristics . | Results (n = 126), No. (%) . |
|---|---|
| Age, median (IQR), y | 59 (49–69) |
| ≥65 y | 48 (38) |
| Male gender | 74 (59) |
| BMI, median (IQR), kg/m2 | 28 (24–34) |
| BMI ≥30 kg/m2 | 54 (43) |
| Baseline CrCl | 94 (67–134) |
| >90 mL/min | 70 (56) |
| 51–90 mL/min | 39 (31) |
| 30–50 mL/min | 10 (9) |
| <30 mL/min | 4 (3) |
| Location before C/T | |
| Community | 71 (56) |
| Hospital | 55 (44) |
| Charlson comorbidity index, median (IQR) | 5 (3–7) |
| Common comorbid conditions | |
| Cardiovascular disease | 85 (67) |
| Diabetes mellitus | 49 (39) |
| Immunocompromised | 49 (39) |
| Asthma/COPD | 29 (23) |
| Malignancy (current) | 28 (22) |
| Chronic kidney disease | 15 (12) |
| Liver disease | 8 (6) |
| Infection type | |
| Bone and joint | 34 (27) |
| Osteomyelitis | 29 |
| Spinal infection | 3 |
| Prosthetic joint infection | 1 |
| Septic arthritis | 1 |
| Urinary tract | 29 (23) |
| Complicated urinary tract infection | 25 |
| Pyelonephritis | 4 |
| Respiratory tract | 23 (18) |
| Pneumonia | 16 |
| Bronchitis | 3 |
| Pansinusitis | 2 |
| Empyema | 1 |
| Otitis media | 1 |
| Intra-abdominal | 20 (16) |
| Complicated intra-abdominal abscess | 13 |
| Diverticulitis | 4 |
| Appendicitis | 2 |
| Peritonitis | 1 |
| Complicated skin and soft tissue | 17 (13) |
| Abscess | 9 |
| Cellulitis | 8 |
| Bacteremia | 3 (3) |
| Endocarditis | 2 |
| CLABSI | 1 |
| Concurrent bacteremia | 12 (10) |
| Intravenous antibiotic therapy before C/T | 63 (50) |
| Characteristics . | Results (n = 126), No. (%) . |
|---|---|
| Age, median (IQR), y | 59 (49–69) |
| ≥65 y | 48 (38) |
| Male gender | 74 (59) |
| BMI, median (IQR), kg/m2 | 28 (24–34) |
| BMI ≥30 kg/m2 | 54 (43) |
| Baseline CrCl | 94 (67–134) |
| >90 mL/min | 70 (56) |
| 51–90 mL/min | 39 (31) |
| 30–50 mL/min | 10 (9) |
| <30 mL/min | 4 (3) |
| Location before C/T | |
| Community | 71 (56) |
| Hospital | 55 (44) |
| Charlson comorbidity index, median (IQR) | 5 (3–7) |
| Common comorbid conditions | |
| Cardiovascular disease | 85 (67) |
| Diabetes mellitus | 49 (39) |
| Immunocompromised | 49 (39) |
| Asthma/COPD | 29 (23) |
| Malignancy (current) | 28 (22) |
| Chronic kidney disease | 15 (12) |
| Liver disease | 8 (6) |
| Infection type | |
| Bone and joint | 34 (27) |
| Osteomyelitis | 29 |
| Spinal infection | 3 |
| Prosthetic joint infection | 1 |
| Septic arthritis | 1 |
| Urinary tract | 29 (23) |
| Complicated urinary tract infection | 25 |
| Pyelonephritis | 4 |
| Respiratory tract | 23 (18) |
| Pneumonia | 16 |
| Bronchitis | 3 |
| Pansinusitis | 2 |
| Empyema | 1 |
| Otitis media | 1 |
| Intra-abdominal | 20 (16) |
| Complicated intra-abdominal abscess | 13 |
| Diverticulitis | 4 |
| Appendicitis | 2 |
| Peritonitis | 1 |
| Complicated skin and soft tissue | 17 (13) |
| Abscess | 9 |
| Cellulitis | 8 |
| Bacteremia | 3 (3) |
| Endocarditis | 2 |
| CLABSI | 1 |
| Concurrent bacteremia | 12 (10) |
| Intravenous antibiotic therapy before C/T | 63 (50) |
Abbreviations: BMI, body mass index; CLABSI, central line bloodstream infection; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; C/T, ceftolozane/tazobactam.
All values represent % of total population unless otherwise indicated.
Estimated using Cockroft-Gault equation, available for 124 of 126 patients.
Including 1 patient on intermittent dialysis.
Due to immunosuppressive medication (chemotherapy, steroids, biologics) or underlying immune deficiency (cancer, AIDS, genetic disorder, autoimmune disease, organ transplant, chronic kidney disease).
Within 72 hours before initiation of C/T for gram-negative pathogens: meropenem (n = 16), imipenem/cilastatin (n = 5), ertapenem (n = 2), cefepime (n = 13), ceftazidime (n = 2), cefotaxime (n = 1), piperacillin/tazobactam (n = 14).
| Characteristics . | Results (n = 126), No. (%) . |
|---|---|
| Age, median (IQR), y | 59 (49–69) |
| ≥65 y | 48 (38) |
| Male gender | 74 (59) |
| BMI, median (IQR), kg/m2 | 28 (24–34) |
| BMI ≥30 kg/m2 | 54 (43) |
| Baseline CrCl | 94 (67–134) |
| >90 mL/min | 70 (56) |
| 51–90 mL/min | 39 (31) |
| 30–50 mL/min | 10 (9) |
| <30 mL/min | 4 (3) |
| Location before C/T | |
| Community | 71 (56) |
| Hospital | 55 (44) |
| Charlson comorbidity index, median (IQR) | 5 (3–7) |
| Common comorbid conditions | |
| Cardiovascular disease | 85 (67) |
| Diabetes mellitus | 49 (39) |
| Immunocompromised | 49 (39) |
| Asthma/COPD | 29 (23) |
| Malignancy (current) | 28 (22) |
| Chronic kidney disease | 15 (12) |
| Liver disease | 8 (6) |
| Infection type | |
| Bone and joint | 34 (27) |
| Osteomyelitis | 29 |
| Spinal infection | 3 |
| Prosthetic joint infection | 1 |
| Septic arthritis | 1 |
| Urinary tract | 29 (23) |
| Complicated urinary tract infection | 25 |
| Pyelonephritis | 4 |
| Respiratory tract | 23 (18) |
| Pneumonia | 16 |
| Bronchitis | 3 |
| Pansinusitis | 2 |
| Empyema | 1 |
| Otitis media | 1 |
| Intra-abdominal | 20 (16) |
| Complicated intra-abdominal abscess | 13 |
| Diverticulitis | 4 |
| Appendicitis | 2 |
| Peritonitis | 1 |
| Complicated skin and soft tissue | 17 (13) |
| Abscess | 9 |
| Cellulitis | 8 |
| Bacteremia | 3 (3) |
| Endocarditis | 2 |
| CLABSI | 1 |
| Concurrent bacteremia | 12 (10) |
| Intravenous antibiotic therapy before C/T | 63 (50) |
| Characteristics . | Results (n = 126), No. (%) . |
|---|---|
| Age, median (IQR), y | 59 (49–69) |
| ≥65 y | 48 (38) |
| Male gender | 74 (59) |
| BMI, median (IQR), kg/m2 | 28 (24–34) |
| BMI ≥30 kg/m2 | 54 (43) |
| Baseline CrCl | 94 (67–134) |
| >90 mL/min | 70 (56) |
| 51–90 mL/min | 39 (31) |
| 30–50 mL/min | 10 (9) |
| <30 mL/min | 4 (3) |
| Location before C/T | |
| Community | 71 (56) |
| Hospital | 55 (44) |
| Charlson comorbidity index, median (IQR) | 5 (3–7) |
| Common comorbid conditions | |
| Cardiovascular disease | 85 (67) |
| Diabetes mellitus | 49 (39) |
| Immunocompromised | 49 (39) |
| Asthma/COPD | 29 (23) |
| Malignancy (current) | 28 (22) |
| Chronic kidney disease | 15 (12) |
| Liver disease | 8 (6) |
| Infection type | |
| Bone and joint | 34 (27) |
| Osteomyelitis | 29 |
| Spinal infection | 3 |
| Prosthetic joint infection | 1 |
| Septic arthritis | 1 |
| Urinary tract | 29 (23) |
| Complicated urinary tract infection | 25 |
| Pyelonephritis | 4 |
| Respiratory tract | 23 (18) |
| Pneumonia | 16 |
| Bronchitis | 3 |
| Pansinusitis | 2 |
| Empyema | 1 |
| Otitis media | 1 |
| Intra-abdominal | 20 (16) |
| Complicated intra-abdominal abscess | 13 |
| Diverticulitis | 4 |
| Appendicitis | 2 |
| Peritonitis | 1 |
| Complicated skin and soft tissue | 17 (13) |
| Abscess | 9 |
| Cellulitis | 8 |
| Bacteremia | 3 (3) |
| Endocarditis | 2 |
| CLABSI | 1 |
| Concurrent bacteremia | 12 (10) |
| Intravenous antibiotic therapy before C/T | 63 (50) |
Abbreviations: BMI, body mass index; CLABSI, central line bloodstream infection; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; C/T, ceftolozane/tazobactam.
All values represent % of total population unless otherwise indicated.
Estimated using Cockroft-Gault equation, available for 124 of 126 patients.
Including 1 patient on intermittent dialysis.
Due to immunosuppressive medication (chemotherapy, steroids, biologics) or underlying immune deficiency (cancer, AIDS, genetic disorder, autoimmune disease, organ transplant, chronic kidney disease).
Within 72 hours before initiation of C/T for gram-negative pathogens: meropenem (n = 16), imipenem/cilastatin (n = 5), ertapenem (n = 2), cefepime (n = 13), ceftazidime (n = 2), cefotaxime (n = 1), piperacillin/tazobactam (n = 14).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
